Physician profile
Michael Chua
NPI 1952832016
$9,172.82
in general payments reported to CMS, 2019-2025
29 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $39.01 · 2021: $1,692 · 2022: $2,322 · 2023: $1,865 · 2024: $1,571 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,001.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,486.91 | 2022-2025 | Envista Mx60 Iol, Amvisc, Miebo |
| Sun Pharmaceutical Industries INC. | $1,330.99 | 2021-2025 | Cequa, Xelpros, Bromsite |
| Alcon Vision LLC | $1,147.62 | 2022-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Abbvie INC. | $1,049.73 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Ivantis, INC | $583.17 | 2021 | |
| Sight Sciences, INC. | $571.17 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Amgen INC. | $358.45 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $338.59 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $331.26 | 2019-2023 | Catalys System, Veritas Vision System, Tecnis Iol |
| Oyster Point Pharma, INC. | $281.84 | 2022-2025 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $247.57 | 2021 | |
| Dompe US, INC. | $200.19 | 2021-2025 | Oxervate |
| Allergan, INC. | $163.03 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $160.76 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $138.69 | 2021-2025 | Acthar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $106.48 | 2024-2025 | Vevye, Iheezo |
| Beaver-Visitec International, INC. | $83.64 | 2022 | |
| Thea Pharma INC. | $81.29 | 2023-2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $79.74 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $76.63 | 2020-2025 | Eylea Hd |
| Eyevance Pharmaceuticals LLC | $72.86 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $61.98 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $53.14 | 2021 | |
| Coopervision INC. | $47.85 | 2022 | |
| Ani Pharmaceuticals, INC. | $38.82 | 2025 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $29.74 | 2025 | Xeomin |
| Biotissue Holdings INC. | $18.15 | 2022 | |
| Rxsight INC | $18.02 | 2022 | |
| Nova Eye, INC. | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.